Unity Biotechnology (UNBX) AI Stock Analysis

• Market Cap: $1.07M
• Dividend Yield: N/A
• Average Volume (3M): 101.71K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.22
• Revenue Growth: N/A
• EPS Growth: 35.08%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 17,212,172
• 10 Day Avg. Volume: 52,616
• 30 Day Avg. Volume: 101,706
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 21.73
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $1.00
• Price Target Upside: 1150.00% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 31 Underperform
• Price Target: ―

Unity Biotechnology's overall score is weighed down by significant financial challenges, including persistent losses and negative equity. Technical analysis suggests a bearish trend with limited momentum. Valuation metrics reflect the unprofitability of the company. However, the recent strategic appointment to the Board provides a potential strategic advantage in its program development.

Positive Factors

Efficacy in specific patient subgroups

UBX1325 generally outperformed aflibercept in the pre-specified subgroup entering the study with CST <400 microns, reflecting 60% of enrolled patients.

Long-term benefits

The Phase 2 BEHOLD study demonstrated statistically significant 48-week benefit in DME with mean change in BCVA +6.2 ETDRS letters from baseline, and 53% of UBX1325 treated patients without requirement of anti-VEGF rescue compared to 22% for sham.

Vision improvement

UBX1325 patients gained 5.2 letters at week 24, and subsequently 5.5 letters at week 36, indicating vision improvement.

Negative Factors

Imbalance in study groups

There were considerably more Vabysmo (faricimab) patients in the UBX1325 group, compared to aflibercept, reflecting a relevant imbalance.

Specific time point underperformance

The miss was driven entirely by the 20-week time point data, which was the only time point over the 36-week study where UBX1325 was inferior to aflibercept.

Study endpoint miss

The previously announced primary endpoint miss for the Phase 2B ASPIRE study comparing UBX1325 and aflibercept in diabetic macular edema patients, not achieving non-inferiority at the average of weeks 20 and 24 primary analysis.

Unity Biotechnology Business Overview & Revenue Model

Company Description

Unity Biotechnology (UBX) is a biotechnology company focused on developing therapeutics to treat age-related diseases. The company's primary aim is to extend healthspan, the period during which individuals remain healthy and free from age-related ailments. Unity Biotechnology's core products target senescent cells, which are cells that have stopped dividing and can contribute to various age-related diseases. By focusing on senescence biology, Unity seeks to develop innovative treatments for conditions such as osteoarthritis and other chronic diseases associated with aging.

How the Company Makes Money

Unity Biotechnology makes money through the development and commercialization of its therapeutic products targeting senescent cells. The company's revenue model primarily relies on milestone payments, licensing deals, and potential royalties from partnerships with larger pharmaceutical companies. Unity may also generate income from collaborations with other biotech firms or research institutions, which can provide funding for research and development activities. Additionally, the company might raise capital through public or private investments to support its ongoing research and clinical trials, which are crucial for bringing its products to market.

Unity Biotechnology Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Unity Biotechnology Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UNBX, the sentiment is Negative. The current price of 0.08 is above the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.14, and below the 200-day MA of 1.01, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 42.19 is Neutral, neither overbought nor oversold. The STOCH value of 31.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for UNBX.

Unity Biotechnology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EQ	56 Neutral	$104.13M	―	-146.92%	―	-61.16%	-139.15%
Sector *	51 Neutral	$7.92B	-0.43	-41.67%	2.21%	22.29%	-1.85%
SNSE	40 Underperform	$11.12M	―	-64.18%	―	―	3.99%
CANF	40 Underperform	$14.14M	―	-122.28%	―	―	―
PMN	38 Underperform	$22.28M	―	-19.56%	―	―	71.47%
EDSA	35 Underperform	$17.81M	―	-69.64%	―	―	22.63%
UNBX	31 Underperform	$1.07M	―	-231.27%	―	―	35.08%

Unity Biotechnology Corporate Events

Unity Biotechnology Appoints Dr. Yehia Hashad to Board

On March 8, 2025, UNITY Biotechnology appointed Dr. Yehia Hashad to its Board of Directors and Science Committee. Dr. Hashad, an experienced ophthalmologist and executive at Bausch + Lomb, brings over 25 years of leadership in global research and development. His expertise is expected to aid UNITY in advancing its UBX1325 program for diabetic macular edema and other ophthalmologic treatments, potentially enhancing the company’s strategic positioning in the biotechnology sector.